Biomarkers could take stigma out of depression

Despite overwhelming scientific evidence that depression is, indeed, a disease, there remains a sometimes-vocal minority of critics who insist that the mood disorder was invented by pharmaceutical companies in order to sell drugs. While it is doubtful that these critics, like all conspiracy theorists, will ever become convinced by facts, a San Diego-based company, Ridge Diagnostics, is hopeful that a blood test that detects biomarkers for Major Depressive Disorder will convince more critics that there is something more than a psychiatrist's opinion involved in the diagnosis. "By having a biological indication of depression, patients and their families have a better understanding of the condition as a medical one, which reduces the stigma of mental health disorders and leads to an improvement in treatment compliance," Lonna J. Williams, Ridge's CEO, says in a release. The quotation comes from a larger article in Psychiatric Times, which outlines the search for blood tests for both depression and schizophrenia. Release | Article

Suggested Articles

The AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.